Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $14.00 per share.
December 8, 2021
· 4 min read